CSL demonstrated solid revenue and profit growth, introduced transformative corporate strategies including a demerger and share buyback, and achieved operational efficiencies. However, challenges in Seqirus revenue growth, impacts from U.S. healthcare reforms, and the need for significant cost reductions in R&D and plasma centers indicate some operational pressures.

Company Guidance

In the CSL Limited Full Year Financial Results call for Fiscal Year 2025, the company reported several key financial metrics and provided guidance for Fiscal Year 2026. The CSL Group achieved a 5% revenue growth on a constant currency basis, with NPATA increasing by 14% and NPAT by 17%. Leverage improved to 1.8x net debt-to-EBITDA, and free cash flow rose by 58%. The final dividend was increased by 12% to USD 1.62 per share. CSL announced major transformational changes expected to yield over USD 0.5 billion in savings by the end of Fiscal Year 2028, with plans to reinvest these savings in high-priority opportunities. Additionally, the company intends to demerge CSL Seqirus as an independent ASX-listed entity in Fiscal Year 2026. For Fiscal Year 2026, CSL anticipates revenue growth of approximately 4% to 5% and NPATA growth of 7% to 10% at constant currency, excluding restructuring costs.

Overall Revenue and Profit Growth

CSL Group revenue grew by 5% on a constant currency basis. NPATA increased by 14% and NPAT grew by 17%.

Dividend Increase

Final dividend increased by 12% to USD 1.62 per share.

Free Cash Flow Improvement

Free cash flow increased by 58%.

Plasma Yield Improvements

Yield improvements are ahead of plan, leading to increased efficiency in plasma collection.

Demerger of CSL Seqirus

Announced intent to demerge CSL Seqirus as an independent ASX-listed entity by fiscal year 2026.

Share Buyback Program

Introduction of a multiyear share buyback program starting with AUD 750 million in FY '26.

Strong Market Leadership in Hemophilia

CSL's hemophilia franchise demonstrated market leadership with growth of 13% at constant currency.

CSL (CSLLY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CSLLY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 10, 2026	2026 (Q2)	- / -	2.074	―	―	―
Aug 18, 2025	2025 (Q4)	- / 1.03	0.763	34.73% (+0.27)
Feb 11, 2025	2025 (Q2)	- / 2.07	1.969	5.33% (+0.10)
Aug 12, 2024	2024 (Q4)	- / 0.77	0.621	23.35% (+0.15)
Feb 12, 2024	2024 (Q2)	- / 1.97	1.701	15.76% (+0.27)
Aug 14, 2023	2023 (Q4)	- / 0.62	0.511	21.53% (+0.11)
Feb 13, 2023	2023 (Q2)	- / 1.70	1.927	-11.73% (-0.23)
Aug 16, 2022	2022 (Q4)	- / 0.51	0.617	-17.18% (-0.11)	―	―
Feb 16, 2022	2022 (Q2)	- / 1.93	1.99	-3.17% (-0.06)	―	―
Aug 17, 2021	2021 (Q4)	- / 0.60	0.961	-37.57% (-0.36)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CSLLY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 18, 2025	$87.04	$72.09	-17.18%
Feb 11, 2025	$79.31	$78.93	-0.48%
Aug 12, 2024	$99.42	$94.98	-4.47%
Feb 12, 2024	$91.87	$88.38	-3.80%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does CSL Limited (CSLLY) report earnings?

CSL Limited (CSLLY) is schdueled to report earning on Feb 10, 2026, TBA (Confirmed).

What is CSL Limited (CSLLY) earnings time?

CSL Limited (CSLLY) earnings time is at Feb 10, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CSLLY EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing